Skip to main content

Table 6 Pathway enrichment analysis of potential target genes in HN2092 for miRNAs responding to therapy in HNSCC patients (FDR < 0.05)

From: Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells

Pathway Number of Proteins in Pathway Proteins from Gene List P-value FDR Genes
ISG15 antiviral mechanism(R) 71 4 0 <1.000E-03 NUP153,EIF4G2,NUP205,KPNA2
Viral carcinogenesis(K) 206 4 0.0006 1.94E-02 KAT2B,RBL2,CCND2,JUN
HTLV-I infection(K) 260 4 0.0013 3.58E-02 KAT2B,MAD2L1,CCND2,JUN
Aurora B signaling(N) 40 3 0.0001 7.00E-03 BIRC5,NPM1,PSMA3
Signaling events mediated by HDAC Class I(N) 56 3 0.0002 1.17E-02 NUP153,KAT2B,YY1
E2F transcription factor network(N) 68 3 0.0003 1.34E-02 KAT2B,RBL2,YY1
Validated targets of C-MYC transcriptional activation(N) 72 3 0.0003 1.35E-02 BIRC5,CCND2,NPM1
Mitotic Prophase(R) 99 3 0.0009 2.79E-02 NUP153,SET,NUP205
Nonsense-Mediated Decay(R) 106 3 0.0010 3.07E-02 SMG7,RPL30,RPL7
Cell cycle(K) 124 3 0.0016 3.55E-02 RBL2,MAD2L1,CCND2
Mitotic G1-G1/S phases(R) 134 3 0.0020 3.66E-02 RBL2,CCND2,PSMA3
Mitotic Metaphase and Anaphase(R) 173 3 0.0042 4.77E-02 BIRC5,MAD2L1,PSMA3
  1. (B) BioCarta, (K) KEGG Pathway, (N) NCI - Nature Curated Data, (P) pantherdb, (R) Reactome